University of North Carolina
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1789-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://northcarolina.edu
Clinical Trials
17
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2008-03-06
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 128
- Registration Number
- NCT00630188
- Locations
- 🇺🇸
Chapel Hill North General Internal Medicine Practice, Chapel Hill, North Carolina, United States
🇺🇸University of North Carolina at Chapel Hill General Medicine Clinic, Chapel Hill, North Carolina, United States
🇺🇸Moses Cone Internal Medicine Practice, Greensboro, North Carolina, United States
Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms
- Conditions
- Pain
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2008-02-20
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 63
- Registration Number
- NCT00618488
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women
- Conditions
- Drug Toxicity
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2007-06-26
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 36
- Registration Number
- NCT00491595
Development and Evaluation of A Mailed Arthritis Self-Management Program
- Conditions
- OsteoarthritisRheumatoid Arthritis
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2007-03-16
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 900
- Registration Number
- NCT00448474
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Improving Medication Use in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2006-10-17
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 492
- Registration Number
- NCT00388817
- Locations
- 🇺🇸
School of Pharmacy, UNC-Chapel Hill, CB 7360, Chapel Hill, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Digital Inhaler Technology Shows Promise for Early COPD Exacerbation Detection
Digital inhalers can detect significant physiologic changes up to two weeks before COPD exacerbations occur, potentially enabling earlier clinical intervention.
Study Identifies Why Venetoclax-Based AML Treatment Fails in Certain Patients
Researchers analyzed 678 AML patients and found that both gene mutations and leukemia cell maturity affect response to venetoclax plus hypomethylating agents treatment.
First Patient Dosed in Phase 2 OASIS Trial of TNX-102 SL for Acute Stress Reaction Following Trauma
Tonix Pharmaceuticals has initiated dosing in the Phase 2 OASIS trial evaluating TNX-102 SL for reducing acute stress reaction severity and acute stress disorder frequency following traumatic events.
Patient-Reported Physical Function Predicts Daratumumab Efficacy in Multiple Myeloma Patients
New research reveals patient-reported physical function serves as a superior prognostic indicator for multiple myeloma treatment outcomes compared to traditional physician assessments.
BioXcel Therapeutics Advances Phase 3 Trials for BXCL501 in Agitation Treatment
BioXcel Therapeutics has initiated the SERENITY At-Home Phase 3 trial evaluating BXCL501 for acute agitation in patients with bipolar disorders or schizophrenia, addressing an estimated 23 million annual episodes.
UNC Researchers Lead Groundbreaking HIV Clinical Trials in Vietnam
UNC researchers Vivian Go and Dr. Bill Miller are conducting multiple clinical trials in Vietnam, focusing on HIV care retention and prevention strategies for high-risk populations.
Maui Derm NP+PA Fall 2024 Conference to Spotlight Latest Advances in Dermatology Treatment
The four-day Maui Derm NP+PA Fall 2024 conference, scheduled for September 15-18 at Gaylord Opryland, will provide comprehensive updates on dermatological advances for nurse practitioners and physician assistants.
Dostarlimab Achieves 100% Complete Response Rate in Rectal Cancer Trial with Mismatch Repair Deficiency
A phase 2 clinical trial at Memorial Sloan Kettering Cancer Center found that dostarlimab achieved complete cancer remission in all 14 patients with locally advanced rectal cancer harboring mismatch repair deficiency mutations.